| Polymersomes for therapeutic delivery of protein and nucleic acid macromolecules: from design to therapeutic applications S Iqbal, M Blenner, A Alexander-Bryant, J Larsen Biomacromolecules 21 (4), 1327-1350, 2020 | 168 | 2020 |
| Vectors for glioblastoma gene therapy: viral & non-viral delivery strategies B Caffery, JS Lee, AA Alexander-Bryant Nanomaterials 9 (1), 105, 2019 | 119 | 2019 |
| Bioengineering strategies for designing targeted cancer therapies AA Alexander-Bryant, WSV Berg-Foels, X Wen Advances in cancer research 118, 1-59, 2013 | 116 | 2013 |
| Peptide-based delivery of therapeutics in cancer treatment T Samec, J Boulos, S Gilmore, A Hazelton, A Alexander-Bryant Materials Today Bio 14, 100248, 2022 | 56 | 2022 |
| Mechanisms of drug resistance in ovarian cancer and associated gene targets KL Alatise, S Gardner, A Alexander-Bryant Cancers 14 (24), 6246, 2022 | 52 | 2022 |
| Nanoparticle delivery systems to combat drug resistance in ovarian cancer EM Miller, TM Samec, AA Alexander-Bryant Nanomedicine: Nanotechnology, Biology and Medicine 31, 102309, 2021 | 45 | 2021 |
| Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo AA Alexander-Bryant, H Zhang, CC Attaway, W Pugh, L Eggart, ... Oral oncology 72, 123-131, 2017 | 34 | 2017 |
| Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo AA Alexander-Bryant, A Dumitriu, CC Attaway, H Yu, A Jakymiw Journal of Controlled Release 218, 72-81, 2015 | 22 | 2015 |
| Factors affecting secondary and supramolecular structures of self‐assembling peptide Nanocarriers ME Pitz, AM Nukovic, MA Elpers, AA Alexander‐Bryant Macromolecular Bioscience 22 (2), 2100347, 2022 | 17 | 2022 |
| Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer T Samec, KL Alatise, J Boulos, S Gilmore, A Hazelton, C Coffin, ... Molecular Therapy-Nucleic Acids 30, 95-111, 2022 | 16 | 2022 |
| In situ photopolymerization of acrylamide hydrogel to coat cellulose acetate nanofibers for drug delivery system MF Attia, AS Montaser, M Arifuzzaman, M Pitz, K Jlassi, ... Polymers 13 (11), 1863, 2021 | 14 | 2021 |
| Classifying changes in LN-18 glial cell morphology: a supervised machine learning approach to analyzing cell microscopy data via FIJI and WEKA S Mbiki, J McClendon, A Alexander-Bryant, J Gilmore Medical & Biological Engineering & Computing 58, 1419-1430, 2020 | 11 | 2020 |
| Enhancing drug delivery with supramolecular amphiphilic macrocycle nanoparticles: selective targeting of CDK4/6 inhibitor palbociclib to melanoma MF Attia, EA Ogunnaike, M Pitz, NM Elbaz, DK Panda, ... Biomaterials science 12 (3), 725-737, 2024 | 2 | 2024 |
| De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells M Pitz, M Elpers, A Nukovic, S Wilde, AJ Gregory, A Alexander-Bryant Biomedicines 10 (9), 2164, 2022 | 2 | 2022 |
| pH-sensitive liposome for siRNA delivery to treat drug-resistant ovarian cancer KL Alatise, S Gardner, A Alexander-Bryant Cancer Research 81 (13_Supplement), 281-281, 2021 | 2 | 2021 |
| Dual Peptide-Mediated Targeted Delivery System A Jakymiw, A Alexander-Bryant US Patent App. 15/074,698, 2016 | 2 | 2016 |
| Tandem peptides targeting HER2 for delivery of CD44 siRNA into HER2+ breast cancer cells in vitro JW Kalogeros, A Miserendino, A Alexander-Bryant, B Booth Cancer Research 83 (7_Supplement), 3979-3979, 2023 | 1 | 2023 |
| Polymer-Mediated Delivery of CRISPR-Cas9 Genome-Editing Therapeutics for CNS Disease S Iqbal, A Alexander-Bryant, J Larsen Engineering Biomaterials for Neural Applications, 229-258, 2022 | 1 | 2022 |
| Cationic cholesterol liposomes for combination therapy to treat drug-resistant ovarian cancer S Gardner, KL Alatise, E Miller, E Grant, A Alexander-Bryant Cancer Research 81 (13_Supplement), 306-306, 2021 | 1 | 2021 |
| Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy T Eckert, MS Zobaer, J Boulos, A Alexander-Bryant, TG Baker, C Rivers, ... Cancers 17 (3), 462, 2025 | | 2025 |
